Loading...
OTCM
PANC
Market cap5kUSD
Nov 03, Last price  
0.00USD
Name

Panacos Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:PANC chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
180k
-36.62%
15,843,04633,800,00037,923,29640,709,94326,892,4914,224,8891,078,0001,337,0001,049,000284,000180,000
Net income
-37m
L-1.71%
-11,699,645-6,400,000-37,329,169-14,980,997-23,419,965-20,039,835-4,508,000-12,038,000-59,078,000-38,110,000-37,459,000
CFO
-31m
L+4.74%
-9,700,000-6,900,000761,860-13,418,973-12,900,188-20,908,723-3,951,000-9,773,000-21,646,000-29,630,000-31,035,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm specializing in the research and development of orally administered small-molecule therapeutics. These innovative drugs are crafted to combat human immunodeficiency virus (HIV) and various other viral diseases affecting humans. The company's scientific methodology concentrates on identifying novel targets within the viral life cycle, specifically focusing on processes like virus maturation and fusion. Currently, their product portfolio includes advanced initiatives, such as second- and third-generation programs, centered on inhibiting HIV maturation. Founded in 1999, the company's main operations are situated in Watertown, Massachusetts.
URL
IPO date
Jun 11, 1998
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show